Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
31,889
archived clinical trials in
Blood Cancer

Phase 2 Study Adding Pracinostat to a Hypomethylating Agent (HMA) in Patients With MDS Who Failed to Respond to Single Agent HMA
A Phase II Simon Two-Stage Study of the Addition of Pracinostat to a Hypomethylating Agent (HMA) in Patients With Myelodysplastic Syndrome (MDS) Who Have Failed to Respond or Maintain a Response to the HMA Alone
Status: Enrolling
Updated:  2/22/2017
U.S.C./Norris Comprehensive Cancer Center
mi
from
Los Angeles, CA
Phase 2 Study Adding Pracinostat to a Hypomethylating Agent (HMA) in Patients With MDS Who Failed to Respond to Single Agent HMA
A Phase II Simon Two-Stage Study of the Addition of Pracinostat to a Hypomethylating Agent (HMA) in Patients With Myelodysplastic Syndrome (MDS) Who Have Failed to Respond or Maintain a Response to the HMA Alone
Status: Enrolling
Updated: 2/22/2017
U.S.C./Norris Comprehensive Cancer Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Phase 2 Study Adding Pracinostat to a Hypomethylating Agent (HMA) in Patients With MDS Who Failed to Respond to Single Agent HMA
A Phase II Simon Two-Stage Study of the Addition of Pracinostat to a Hypomethylating Agent (HMA) in Patients With Myelodysplastic Syndrome (MDS) Who Have Failed to Respond or Maintain a Response to the HMA Alone
Status: Enrolling
Updated:  2/22/2017
Yale School of Medicine
mi
from
New Haven, CT
Phase 2 Study Adding Pracinostat to a Hypomethylating Agent (HMA) in Patients With MDS Who Failed to Respond to Single Agent HMA
A Phase II Simon Two-Stage Study of the Addition of Pracinostat to a Hypomethylating Agent (HMA) in Patients With Myelodysplastic Syndrome (MDS) Who Have Failed to Respond or Maintain a Response to the HMA Alone
Status: Enrolling
Updated: 2/22/2017
Yale School of Medicine
mi
from
New Haven, CT
Click here to add this to my saved trials
Phase 2 Study Adding Pracinostat to a Hypomethylating Agent (HMA) in Patients With MDS Who Failed to Respond to Single Agent HMA
A Phase II Simon Two-Stage Study of the Addition of Pracinostat to a Hypomethylating Agent (HMA) in Patients With Myelodysplastic Syndrome (MDS) Who Have Failed to Respond or Maintain a Response to the HMA Alone
Status: Enrolling
Updated:  2/22/2017
City of Hope
mi
from
Duarte, CA
Phase 2 Study Adding Pracinostat to a Hypomethylating Agent (HMA) in Patients With MDS Who Failed to Respond to Single Agent HMA
A Phase II Simon Two-Stage Study of the Addition of Pracinostat to a Hypomethylating Agent (HMA) in Patients With Myelodysplastic Syndrome (MDS) Who Have Failed to Respond or Maintain a Response to the HMA Alone
Status: Enrolling
Updated: 2/22/2017
City of Hope
mi
from
Duarte, CA
Click here to add this to my saved trials
Phase 2 Study Adding Pracinostat to a Hypomethylating Agent (HMA) in Patients With MDS Who Failed to Respond to Single Agent HMA
A Phase II Simon Two-Stage Study of the Addition of Pracinostat to a Hypomethylating Agent (HMA) in Patients With Myelodysplastic Syndrome (MDS) Who Have Failed to Respond or Maintain a Response to the HMA Alone
Status: Enrolling
Updated:  2/22/2017
Northwestern University
mi
from
Chicago, IL
Phase 2 Study Adding Pracinostat to a Hypomethylating Agent (HMA) in Patients With MDS Who Failed to Respond to Single Agent HMA
A Phase II Simon Two-Stage Study of the Addition of Pracinostat to a Hypomethylating Agent (HMA) in Patients With Myelodysplastic Syndrome (MDS) Who Have Failed to Respond or Maintain a Response to the HMA Alone
Status: Enrolling
Updated: 2/22/2017
Northwestern University
mi
from
Chicago, IL
Click here to add this to my saved trials
Phase 2 Study Adding Pracinostat to a Hypomethylating Agent (HMA) in Patients With MDS Who Failed to Respond to Single Agent HMA
A Phase II Simon Two-Stage Study of the Addition of Pracinostat to a Hypomethylating Agent (HMA) in Patients With Myelodysplastic Syndrome (MDS) Who Have Failed to Respond or Maintain a Response to the HMA Alone
Status: Enrolling
Updated:  2/22/2017
University of Texas Southwestern
mi
from
Dallas, TX
Phase 2 Study Adding Pracinostat to a Hypomethylating Agent (HMA) in Patients With MDS Who Failed to Respond to Single Agent HMA
A Phase II Simon Two-Stage Study of the Addition of Pracinostat to a Hypomethylating Agent (HMA) in Patients With Myelodysplastic Syndrome (MDS) Who Have Failed to Respond or Maintain a Response to the HMA Alone
Status: Enrolling
Updated: 2/22/2017
University of Texas Southwestern
mi
from
Dallas, TX
Click here to add this to my saved trials
Phase 2 Study Adding Pracinostat to a Hypomethylating Agent (HMA) in Patients With MDS Who Failed to Respond to Single Agent HMA
A Phase II Simon Two-Stage Study of the Addition of Pracinostat to a Hypomethylating Agent (HMA) in Patients With Myelodysplastic Syndrome (MDS) Who Have Failed to Respond or Maintain a Response to the HMA Alone
Status: Enrolling
Updated:  2/22/2017
M.D. Anderson Cancer Center
mi
from
Houston, TX
Phase 2 Study Adding Pracinostat to a Hypomethylating Agent (HMA) in Patients With MDS Who Failed to Respond to Single Agent HMA
A Phase II Simon Two-Stage Study of the Addition of Pracinostat to a Hypomethylating Agent (HMA) in Patients With Myelodysplastic Syndrome (MDS) Who Have Failed to Respond or Maintain a Response to the HMA Alone
Status: Enrolling
Updated: 2/22/2017
M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Granulocyte-colony Stimulating Factor (G-CSF) and Plerixafor Plus Sorafenib for Acute Myelogenous Leukemia (AML) With FLT3 Mutations
G-CSF and Plerixafor With Sorafenib for Acute Myelogenous Leukemia With FLT3 Mutations
Status: Enrolling
Updated:  2/23/2017
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Granulocyte-colony Stimulating Factor (G-CSF) and Plerixafor Plus Sorafenib for Acute Myelogenous Leukemia (AML) With FLT3 Mutations
G-CSF and Plerixafor With Sorafenib for Acute Myelogenous Leukemia With FLT3 Mutations
Status: Enrolling
Updated: 2/23/2017
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Study for the Treatment of Transfusional Iron Overload in Myelodysplastic Patients
An Open Label, Safety and Tolerability Study of Deferasirox for Treatment of Transfusional Iron Overload in Low-Risk and INT-1 Myelodysplastic Patients
Status: Enrolling
Updated:  2/28/2017
Stanford Univ Med Ctr
mi
from
Stanford, CA
Study for the Treatment of Transfusional Iron Overload in Myelodysplastic Patients
An Open Label, Safety and Tolerability Study of Deferasirox for Treatment of Transfusional Iron Overload in Low-Risk and INT-1 Myelodysplastic Patients
Status: Enrolling
Updated: 2/28/2017
Stanford Univ Med Ctr
mi
from
Stanford, CA
Click here to add this to my saved trials
Study for the Treatment of Transfusional Iron Overload in Myelodysplastic Patients
An Open Label, Safety and Tolerability Study of Deferasirox for Treatment of Transfusional Iron Overload in Low-Risk and INT-1 Myelodysplastic Patients
Status: Enrolling
Updated:  2/28/2017
Karmanos Cancer Center
mi
from
Detroit, MI
Study for the Treatment of Transfusional Iron Overload in Myelodysplastic Patients
An Open Label, Safety and Tolerability Study of Deferasirox for Treatment of Transfusional Iron Overload in Low-Risk and INT-1 Myelodysplastic Patients
Status: Enrolling
Updated: 2/28/2017
Karmanos Cancer Center
mi
from
Detroit, MI
Click here to add this to my saved trials
Study for the Treatment of Transfusional Iron Overload in Myelodysplastic Patients
An Open Label, Safety and Tolerability Study of Deferasirox for Treatment of Transfusional Iron Overload in Low-Risk and INT-1 Myelodysplastic Patients
Status: Enrolling
Updated:  2/28/2017
M.D. Anderson Cancer Center
mi
from
Houston, TX
Study for the Treatment of Transfusional Iron Overload in Myelodysplastic Patients
An Open Label, Safety and Tolerability Study of Deferasirox for Treatment of Transfusional Iron Overload in Low-Risk and INT-1 Myelodysplastic Patients
Status: Enrolling
Updated: 2/28/2017
M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Phase I/II Study of DFP-10917 in Patients With Acute Leukemia
A Phase I/II Study of DFP 10917 Given by Continuous Infusion in Patients With Relapsed or Refractory Acute Leukemia
Status: Enrolling
Updated:  3/2/2017
M.D. Anderson Cancer Center
mi
from
Houston, TX
Phase I/II Study of DFP-10917 in Patients With Acute Leukemia
A Phase I/II Study of DFP 10917 Given by Continuous Infusion in Patients With Relapsed or Refractory Acute Leukemia
Status: Enrolling
Updated: 3/2/2017
M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Arsenic Trioxide in Combination With Cytarabine in Patients With High-risk MDS and Poor-prognosis AML
Phase I/II Study of Arsenic Trioxide in Combination With Cytosine Arabinoside in Patients With High-risk Myelodysplastic Syndrome and Poor-prognosis Acute Myelogenous Leukemia
Status: Enrolling
Updated:  3/2/2017
Weill Medcial College of Cornell University
mi
from
New York, NY
Arsenic Trioxide in Combination With Cytarabine in Patients With High-risk MDS and Poor-prognosis AML
Phase I/II Study of Arsenic Trioxide in Combination With Cytosine Arabinoside in Patients With High-risk Myelodysplastic Syndrome and Poor-prognosis Acute Myelogenous Leukemia
Status: Enrolling
Updated: 3/2/2017
Weill Medcial College of Cornell University
mi
from
New York, NY
Click here to add this to my saved trials
Exergaming Intervention in ALL Patients
The Effect of a Home-based Fitness Intervention on Cardiometabolic Risk Profile in Acute Lymphoblastic Leukemia (ALL) Patients
Status: Enrolling
Updated:  3/13/2017
University of Minnesota Amplatz Children's Hospital
mi
from
Minneapolis, MN
Exergaming Intervention in ALL Patients
The Effect of a Home-based Fitness Intervention on Cardiometabolic Risk Profile in Acute Lymphoblastic Leukemia (ALL) Patients
Status: Enrolling
Updated: 3/13/2017
University of Minnesota Amplatz Children's Hospital
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Genomic and Psychosocial Effects of the 3RP on Patients With MGUS and Smoldering Multiple Myeloma
Genomic and Psychosocial Effects of the Relaxation Response Resiliency Program (3RP) on Patients With MGUS and Smoldering Multiple Myeloma
Status: Enrolling
Updated:  3/15/2017
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
Genomic and Psychosocial Effects of the 3RP on Patients With MGUS and Smoldering Multiple Myeloma
Genomic and Psychosocial Effects of the Relaxation Response Resiliency Program (3RP) on Patients With MGUS and Smoldering Multiple Myeloma
Status: Enrolling
Updated: 3/15/2017
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
Click here to add this to my saved trials
Genomic and Psychosocial Effects of the 3RP on Patients With MGUS and Smoldering Multiple Myeloma
Genomic and Psychosocial Effects of the Relaxation Response Resiliency Program (3RP) on Patients With MGUS and Smoldering Multiple Myeloma
Status: Enrolling
Updated:  3/15/2017
Dana-Farber Cancer Institute
mi
from
Boston, MA
Genomic and Psychosocial Effects of the 3RP on Patients With MGUS and Smoldering Multiple Myeloma
Genomic and Psychosocial Effects of the Relaxation Response Resiliency Program (3RP) on Patients With MGUS and Smoldering Multiple Myeloma
Status: Enrolling
Updated: 3/15/2017
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
Genomic and Psychosocial Effects of the 3RP on Patients With MGUS and Smoldering Multiple Myeloma
Genomic and Psychosocial Effects of the Relaxation Response Resiliency Program (3RP) on Patients With MGUS and Smoldering Multiple Myeloma
Status: Enrolling
Updated:  3/15/2017
Massachusetts General Hospital
mi
from
Boston, MA
Genomic and Psychosocial Effects of the 3RP on Patients With MGUS and Smoldering Multiple Myeloma
Genomic and Psychosocial Effects of the Relaxation Response Resiliency Program (3RP) on Patients With MGUS and Smoldering Multiple Myeloma
Status: Enrolling
Updated: 3/15/2017
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
PCI-32765 (Ibrutinib) in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or B-cell Prolymphocytic Leukemia
A Phase 2 Study of the Bruton's Tyrosine Kinase (Btk) Inhibitor, PCI-32765(Ibrutinib), in Relapsed and Refractory Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) and B-cell Prolymphocytic Leukemia (B-PLL)
Status: Enrolling
Updated:  3/20/2017
Ohio State University Medical Center
mi
from
Columbus, OH
PCI-32765 (Ibrutinib) in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or B-cell Prolymphocytic Leukemia
A Phase 2 Study of the Bruton's Tyrosine Kinase (Btk) Inhibitor, PCI-32765(Ibrutinib), in Relapsed and Refractory Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) and B-cell Prolymphocytic Leukemia (B-PLL)
Status: Enrolling
Updated: 3/20/2017
Ohio State University Medical Center
mi
from
Columbus, OH
Click here to add this to my saved trials
Sorafenib Maintenance Therapy for Patients With AML After Allogeneic Stem Cell Transplant
Phase I Trial of Sorafenib Maintenance Therapy for Patients With FLT3-ITD AML After Allogeneic Stem Cell Transplantation
Status: Enrolling
Updated:  3/21/2017
Massachusetts General Hospital
mi
from
Boston, MA
Sorafenib Maintenance Therapy for Patients With AML After Allogeneic Stem Cell Transplant
Phase I Trial of Sorafenib Maintenance Therapy for Patients With FLT3-ITD AML After Allogeneic Stem Cell Transplantation
Status: Enrolling
Updated: 3/21/2017
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
Sorafenib Maintenance Therapy for Patients With AML After Allogeneic Stem Cell Transplant
Phase I Trial of Sorafenib Maintenance Therapy for Patients With FLT3-ITD AML After Allogeneic Stem Cell Transplantation
Status: Enrolling
Updated:  3/21/2017
Dana-Farber Cancer Institute
mi
from
Boston, MA
Sorafenib Maintenance Therapy for Patients With AML After Allogeneic Stem Cell Transplant
Phase I Trial of Sorafenib Maintenance Therapy for Patients With FLT3-ITD AML After Allogeneic Stem Cell Transplantation
Status: Enrolling
Updated: 3/21/2017
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
Busulfan/Clofarabine + Allogeneic Stem Cell Transplantation
Phase II Study of Reduced Intensity Conditioning With Busulfan/Clofarabine Followed by Allogeneic Stem Cell Transplantation
Status: Enrolling
Updated:  3/21/2017
Massachusetts General Hospital
mi
from
Boston, MA
Busulfan/Clofarabine + Allogeneic Stem Cell Transplantation
Phase II Study of Reduced Intensity Conditioning With Busulfan/Clofarabine Followed by Allogeneic Stem Cell Transplantation
Status: Enrolling
Updated: 3/21/2017
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
Busulfan/Clofarabine + Allogeneic Stem Cell Transplantation
Phase II Study of Reduced Intensity Conditioning With Busulfan/Clofarabine Followed by Allogeneic Stem Cell Transplantation
Status: Enrolling
Updated:  3/21/2017
Brigham and Women's Hosp
mi
from
Boston, MA
Busulfan/Clofarabine + Allogeneic Stem Cell Transplantation
Phase II Study of Reduced Intensity Conditioning With Busulfan/Clofarabine Followed by Allogeneic Stem Cell Transplantation
Status: Enrolling
Updated: 3/21/2017
Brigham and Women's Hosp
mi
from
Boston, MA
Click here to add this to my saved trials
Busulfan/Clofarabine + Allogeneic Stem Cell Transplantation
Phase II Study of Reduced Intensity Conditioning With Busulfan/Clofarabine Followed by Allogeneic Stem Cell Transplantation
Status: Enrolling
Updated:  3/21/2017
Dana-Farber Cancer Institute
mi
from
Boston, MA
Busulfan/Clofarabine + Allogeneic Stem Cell Transplantation
Phase II Study of Reduced Intensity Conditioning With Busulfan/Clofarabine Followed by Allogeneic Stem Cell Transplantation
Status: Enrolling
Updated: 3/21/2017
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
Bendamustine Hydrochloride, Clofarabine, and Etoposide in Treating Younger Patients With Relapsed or Refractory Hematologic Malignancies
A Phase I Trial of Bendamustine in Combination With Clofarabine and Etoposide in Pediatric Patients With Relapsed or Refractory Hematologic Malignancies
Status: Enrolling
Updated:  3/21/2017
St. Jude Children's Research Hospital
mi
from
Memphis, TN
Bendamustine Hydrochloride, Clofarabine, and Etoposide in Treating Younger Patients With Relapsed or Refractory Hematologic Malignancies
A Phase I Trial of Bendamustine in Combination With Clofarabine and Etoposide in Pediatric Patients With Relapsed or Refractory Hematologic Malignancies
Status: Enrolling
Updated: 3/21/2017
St. Jude Children's Research Hospital
mi
from
Memphis, TN
Click here to add this to my saved trials
Safety Study of Mocetinostat in Combination With Azacitidine in Subjects With MDS
A Phase I/II, Multi-Center Study of Mocetinostat (MGCD0103) in Combination With Azacitidine in Subjects With Intermediate or High Risk Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated:  3/21/2017
Georegetown University
mi
from
Washington,
Safety Study of Mocetinostat in Combination With Azacitidine in Subjects With MDS
A Phase I/II, Multi-Center Study of Mocetinostat (MGCD0103) in Combination With Azacitidine in Subjects With Intermediate or High Risk Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated: 3/21/2017
Georegetown University
mi
from
Washington,
Click here to add this to my saved trials
Safety Study of Mocetinostat in Combination With Azacitidine in Subjects With MDS
A Phase I/II, Multi-Center Study of Mocetinostat (MGCD0103) in Combination With Azacitidine in Subjects With Intermediate or High Risk Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated:  3/21/2017
Lakes Research
mi
from
Miami Lakes, FL
Safety Study of Mocetinostat in Combination With Azacitidine in Subjects With MDS
A Phase I/II, Multi-Center Study of Mocetinostat (MGCD0103) in Combination With Azacitidine in Subjects With Intermediate or High Risk Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated: 3/21/2017
Lakes Research
mi
from
Miami Lakes, FL
Click here to add this to my saved trials
Safety Study of Mocetinostat in Combination With Azacitidine in Subjects With MDS
A Phase I/II, Multi-Center Study of Mocetinostat (MGCD0103) in Combination With Azacitidine in Subjects With Intermediate or High Risk Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated:  3/21/2017
Norris Cotton Cancer Center at Dartmouth-Hitchcock Medical Center
mi
from
Lebanon, NH
Safety Study of Mocetinostat in Combination With Azacitidine in Subjects With MDS
A Phase I/II, Multi-Center Study of Mocetinostat (MGCD0103) in Combination With Azacitidine in Subjects With Intermediate or High Risk Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated: 3/21/2017
Norris Cotton Cancer Center at Dartmouth-Hitchcock Medical Center
mi
from
Lebanon, NH
Click here to add this to my saved trials
Safety Study of Mocetinostat in Combination With Azacitidine in Subjects With MDS
A Phase I/II, Multi-Center Study of Mocetinostat (MGCD0103) in Combination With Azacitidine in Subjects With Intermediate or High Risk Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated:  3/21/2017
New York Medical College
mi
from
Valhalla, NY
Safety Study of Mocetinostat in Combination With Azacitidine in Subjects With MDS
A Phase I/II, Multi-Center Study of Mocetinostat (MGCD0103) in Combination With Azacitidine in Subjects With Intermediate or High Risk Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated: 3/21/2017
New York Medical College
mi
from
Valhalla, NY
Click here to add this to my saved trials
Safety Study of Mocetinostat in Combination With Azacitidine in Subjects With MDS
A Phase I/II, Multi-Center Study of Mocetinostat (MGCD0103) in Combination With Azacitidine in Subjects With Intermediate or High Risk Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated:  3/21/2017
Duke Univ Med Ctr
mi
from
Durham, NC
Safety Study of Mocetinostat in Combination With Azacitidine in Subjects With MDS
A Phase I/II, Multi-Center Study of Mocetinostat (MGCD0103) in Combination With Azacitidine in Subjects With Intermediate or High Risk Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated: 3/21/2017
Duke Univ Med Ctr
mi
from
Durham, NC
Click here to add this to my saved trials
Safety Study of Mocetinostat in Combination With Azacitidine in Subjects With MDS
A Phase I/II, Multi-Center Study of Mocetinostat (MGCD0103) in Combination With Azacitidine in Subjects With Intermediate or High Risk Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated:  3/21/2017
St. Francis Hospital
mi
from
Greenville, SC
Safety Study of Mocetinostat in Combination With Azacitidine in Subjects With MDS
A Phase I/II, Multi-Center Study of Mocetinostat (MGCD0103) in Combination With Azacitidine in Subjects With Intermediate or High Risk Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated: 3/21/2017
St. Francis Hospital
mi
from
Greenville, SC
Click here to add this to my saved trials
Safety Study of Mocetinostat in Combination With Azacitidine in Subjects With MDS
A Phase I/II, Multi-Center Study of Mocetinostat (MGCD0103) in Combination With Azacitidine in Subjects With Intermediate or High Risk Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated:  3/21/2017
Cancer Care Centers of South Texas
mi
from
New Braunfels, TX
Safety Study of Mocetinostat in Combination With Azacitidine in Subjects With MDS
A Phase I/II, Multi-Center Study of Mocetinostat (MGCD0103) in Combination With Azacitidine in Subjects With Intermediate or High Risk Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated: 3/21/2017
Cancer Care Centers of South Texas
mi
from
New Braunfels, TX
Click here to add this to my saved trials
Safety Study of Mocetinostat in Combination With Azacitidine in Subjects With MDS
A Phase I/II, Multi-Center Study of Mocetinostat (MGCD0103) in Combination With Azacitidine in Subjects With Intermediate or High Risk Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated:  3/21/2017
Cancer Care Centers of South Texas
mi
from
San Antonio, TX
Safety Study of Mocetinostat in Combination With Azacitidine in Subjects With MDS
A Phase I/II, Multi-Center Study of Mocetinostat (MGCD0103) in Combination With Azacitidine in Subjects With Intermediate or High Risk Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated: 3/21/2017
Cancer Care Centers of South Texas
mi
from
San Antonio, TX
Click here to add this to my saved trials
Safety Study of Mocetinostat in Combination With Azacitidine in Subjects With MDS
A Phase I/II, Multi-Center Study of Mocetinostat (MGCD0103) in Combination With Azacitidine in Subjects With Intermediate or High Risk Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated:  3/21/2017
Fletcher Allen Health Care and Vermont Cancer Center
mi
from
Burlington, VT
Safety Study of Mocetinostat in Combination With Azacitidine in Subjects With MDS
A Phase I/II, Multi-Center Study of Mocetinostat (MGCD0103) in Combination With Azacitidine in Subjects With Intermediate or High Risk Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated: 3/21/2017
Fletcher Allen Health Care and Vermont Cancer Center
mi
from
Burlington, VT
Click here to add this to my saved trials
Safety Study of Mocetinostat in Combination With Azacitidine in Subjects With MDS
A Phase I/II, Multi-Center Study of Mocetinostat (MGCD0103) in Combination With Azacitidine in Subjects With Intermediate or High Risk Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated:  3/21/2017
The Mayo Clinic
mi
from
Rochester, MN
Safety Study of Mocetinostat in Combination With Azacitidine in Subjects With MDS
A Phase I/II, Multi-Center Study of Mocetinostat (MGCD0103) in Combination With Azacitidine in Subjects With Intermediate or High Risk Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated: 3/21/2017
The Mayo Clinic
mi
from
Rochester, MN
Click here to add this to my saved trials
A Trial In Patients With Advanced Cancer And Leukemia
A Phase I Trial Of Pf-03084014 In Patients With Advanced Solid Tumor Malignancy And T-cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma
Status: Enrolling
Updated:  4/3/2017
Anschutz Cancer Pavilion
mi
from
Aurora, CO
A Trial In Patients With Advanced Cancer And Leukemia
A Phase I Trial Of Pf-03084014 In Patients With Advanced Solid Tumor Malignancy And T-cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma
Status: Enrolling
Updated: 4/3/2017
Anschutz Cancer Pavilion
mi
from
Aurora, CO
Click here to add this to my saved trials
A Trial In Patients With Advanced Cancer And Leukemia
A Phase I Trial Of Pf-03084014 In Patients With Advanced Solid Tumor Malignancy And T-cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma
Status: Enrolling
Updated:  4/3/2017
University of Colorado Denver (CTRC)
mi
from
Aurora, CO
A Trial In Patients With Advanced Cancer And Leukemia
A Phase I Trial Of Pf-03084014 In Patients With Advanced Solid Tumor Malignancy And T-cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma
Status: Enrolling
Updated: 4/3/2017
University of Colorado Denver (CTRC)
mi
from
Aurora, CO
Click here to add this to my saved trials
A Trial In Patients With Advanced Cancer And Leukemia
A Phase I Trial Of Pf-03084014 In Patients With Advanced Solid Tumor Malignancy And T-cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma
Status: Enrolling
Updated:  4/3/2017
University of Colorado Hospital
mi
from
Aurora, CO
A Trial In Patients With Advanced Cancer And Leukemia
A Phase I Trial Of Pf-03084014 In Patients With Advanced Solid Tumor Malignancy And T-cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma
Status: Enrolling
Updated: 4/3/2017
University of Colorado Hospital
mi
from
Aurora, CO
Click here to add this to my saved trials
A Trial In Patients With Advanced Cancer And Leukemia
A Phase I Trial Of Pf-03084014 In Patients With Advanced Solid Tumor Malignancy And T-cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma
Status: Enrolling
Updated:  4/3/2017
Massachusetts General Hospital Clinical Laboratory
mi
from
Boston, MA
A Trial In Patients With Advanced Cancer And Leukemia
A Phase I Trial Of Pf-03084014 In Patients With Advanced Solid Tumor Malignancy And T-cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma
Status: Enrolling
Updated: 4/3/2017
Massachusetts General Hospital Clinical Laboratory
mi
from
Boston, MA
Click here to add this to my saved trials
A Trial In Patients With Advanced Cancer And Leukemia
A Phase I Trial Of Pf-03084014 In Patients With Advanced Solid Tumor Malignancy And T-cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma
Status: Enrolling
Updated:  4/3/2017
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
A Trial In Patients With Advanced Cancer And Leukemia
A Phase I Trial Of Pf-03084014 In Patients With Advanced Solid Tumor Malignancy And T-cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma
Status: Enrolling
Updated: 4/3/2017
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
Click here to add this to my saved trials
A Trial In Patients With Advanced Cancer And Leukemia
A Phase I Trial Of Pf-03084014 In Patients With Advanced Solid Tumor Malignancy And T-cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma
Status: Enrolling
Updated:  4/3/2017
Dana Ferber Cancer institute
mi
from
Boston, MA
A Trial In Patients With Advanced Cancer And Leukemia
A Phase I Trial Of Pf-03084014 In Patients With Advanced Solid Tumor Malignancy And T-cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma
Status: Enrolling
Updated: 4/3/2017
Dana Ferber Cancer institute
mi
from
Boston, MA
Click here to add this to my saved trials
A Trial In Patients With Advanced Cancer And Leukemia
A Phase I Trial Of Pf-03084014 In Patients With Advanced Solid Tumor Malignancy And T-cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma
Status: Enrolling
Updated:  4/3/2017
Karmanos Cancer Center/Wayne State University
mi
from
Detroit, MI
A Trial In Patients With Advanced Cancer And Leukemia
A Phase I Trial Of Pf-03084014 In Patients With Advanced Solid Tumor Malignancy And T-cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma
Status: Enrolling
Updated: 4/3/2017
Karmanos Cancer Center/Wayne State University
mi
from
Detroit, MI
Click here to add this to my saved trials
A Trial In Patients With Advanced Cancer And Leukemia
A Phase I Trial Of Pf-03084014 In Patients With Advanced Solid Tumor Malignancy And T-cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma
Status: Enrolling
Updated:  4/3/2017
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
A Trial In Patients With Advanced Cancer And Leukemia
A Phase I Trial Of Pf-03084014 In Patients With Advanced Solid Tumor Malignancy And T-cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma
Status: Enrolling
Updated: 4/3/2017
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
A Trial In Patients With Advanced Cancer And Leukemia
A Phase I Trial Of Pf-03084014 In Patients With Advanced Solid Tumor Malignancy And T-cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma
Status: Enrolling
Updated:  4/3/2017
DIPRTMNT CLIN Scienze RADIOL e Istocitopatologiche
mi
from
Bologna,
A Trial In Patients With Advanced Cancer And Leukemia
A Phase I Trial Of Pf-03084014 In Patients With Advanced Solid Tumor Malignancy And T-cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma
Status: Enrolling
Updated: 4/3/2017
DIPRTMNT CLIN Scienze RADIOL e Istocitopatologiche
mi
from
Bologna,
Click here to add this to my saved trials
Delayed Effects of Treatment in Cancer Survivors (DETECS)
Delayed Effects of Treatment in Cancer Survivors (DETECS)
Status: Enrolling
Updated:  4/3/2017
University of Colorado Clinical and Translational Research Center
mi
from
Aurora, CO
Delayed Effects of Treatment in Cancer Survivors (DETECS)
Delayed Effects of Treatment in Cancer Survivors (DETECS)
Status: Enrolling
Updated: 4/3/2017
University of Colorado Clinical and Translational Research Center
mi
from
Aurora, CO
Click here to add this to my saved trials
Cognitive-Behavioral Intervention for Worry, Uncertainty, and Insomnia for Cancer Survivors
Worry, Uncertainty and Insomnia: A Cognitive-behavioral Intervention for Cancer Survivors
Status: Enrolling
Updated:  4/4/2017
Wexner Medical Center at The Ohio State University Department of Psychiatry
mi
from
Columbus, OH
Cognitive-Behavioral Intervention for Worry, Uncertainty, and Insomnia for Cancer Survivors
Worry, Uncertainty and Insomnia: A Cognitive-behavioral Intervention for Cancer Survivors
Status: Enrolling
Updated: 4/4/2017
Wexner Medical Center at The Ohio State University Department of Psychiatry
mi
from
Columbus, OH
Click here to add this to my saved trials
Tipifarnib in Treating Patients With Anemia or Neutropenia and Large Granular Lymphocyte Leukemia
A Phase 2 Study of Tipifarnib in Large Granular Lymphocyte (LGL) Leukemia
Status: Enrolling
Updated:  4/4/2017
Case Western Reserve Univ
mi
from
Cleveland, OH
Tipifarnib in Treating Patients With Anemia or Neutropenia and Large Granular Lymphocyte Leukemia
A Phase 2 Study of Tipifarnib in Large Granular Lymphocyte (LGL) Leukemia
Status: Enrolling
Updated: 4/4/2017
Case Western Reserve Univ
mi
from
Cleveland, OH
Click here to add this to my saved trials
Study of ACY-1215 Alone and in Combination With Bortezomib and Dexamethasone in Multiple Myeloma
A Phase 1/2, Open-Label, Multicenter Study of ACY-1215 Administered Orally as Monotherapy and in Combination With Bortezomib and Dexamethasone for the Treatment of Relapsed or Relapsed/Refractory Multiple Myeloma
Status: Enrolling
Updated:  4/5/2017
Winship Cancer Institute at Emory University
mi
from
Atlanta, GA
Study of ACY-1215 Alone and in Combination With Bortezomib and Dexamethasone in Multiple Myeloma
A Phase 1/2, Open-Label, Multicenter Study of ACY-1215 Administered Orally as Monotherapy and in Combination With Bortezomib and Dexamethasone for the Treatment of Relapsed or Relapsed/Refractory Multiple Myeloma
Status: Enrolling
Updated: 4/5/2017
Winship Cancer Institute at Emory University
mi
from
Atlanta, GA
Click here to add this to my saved trials
Study of ACY-1215 Alone and in Combination With Bortezomib and Dexamethasone in Multiple Myeloma
A Phase 1/2, Open-Label, Multicenter Study of ACY-1215 Administered Orally as Monotherapy and in Combination With Bortezomib and Dexamethasone for the Treatment of Relapsed or Relapsed/Refractory Multiple Myeloma
Status: Enrolling
Updated:  4/5/2017
Massachusetts General Hospital
mi
from
Boston, MA
Study of ACY-1215 Alone and in Combination With Bortezomib and Dexamethasone in Multiple Myeloma
A Phase 1/2, Open-Label, Multicenter Study of ACY-1215 Administered Orally as Monotherapy and in Combination With Bortezomib and Dexamethasone for the Treatment of Relapsed or Relapsed/Refractory Multiple Myeloma
Status: Enrolling
Updated: 4/5/2017
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
Study of ACY-1215 Alone and in Combination With Bortezomib and Dexamethasone in Multiple Myeloma
A Phase 1/2, Open-Label, Multicenter Study of ACY-1215 Administered Orally as Monotherapy and in Combination With Bortezomib and Dexamethasone for the Treatment of Relapsed or Relapsed/Refractory Multiple Myeloma
Status: Enrolling
Updated:  4/5/2017
Mt. Sinai Medical Center
mi
from
New York, NY
Study of ACY-1215 Alone and in Combination With Bortezomib and Dexamethasone in Multiple Myeloma
A Phase 1/2, Open-Label, Multicenter Study of ACY-1215 Administered Orally as Monotherapy and in Combination With Bortezomib and Dexamethasone for the Treatment of Relapsed or Relapsed/Refractory Multiple Myeloma
Status: Enrolling
Updated: 4/5/2017
Mt. Sinai Medical Center
mi
from
New York, NY
Click here to add this to my saved trials
Study of ACY-1215 Alone and in Combination With Bortezomib and Dexamethasone in Multiple Myeloma
A Phase 1/2, Open-Label, Multicenter Study of ACY-1215 Administered Orally as Monotherapy and in Combination With Bortezomib and Dexamethasone for the Treatment of Relapsed or Relapsed/Refractory Multiple Myeloma
Status: Enrolling
Updated:  4/5/2017
Univ of Pennsylvania
mi
from
Philadelphia, PA
Study of ACY-1215 Alone and in Combination With Bortezomib and Dexamethasone in Multiple Myeloma
A Phase 1/2, Open-Label, Multicenter Study of ACY-1215 Administered Orally as Monotherapy and in Combination With Bortezomib and Dexamethasone for the Treatment of Relapsed or Relapsed/Refractory Multiple Myeloma
Status: Enrolling
Updated: 4/5/2017
Univ of Pennsylvania
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Study of ACY-1215 Alone and in Combination With Bortezomib and Dexamethasone in Multiple Myeloma
A Phase 1/2, Open-Label, Multicenter Study of ACY-1215 Administered Orally as Monotherapy and in Combination With Bortezomib and Dexamethasone for the Treatment of Relapsed or Relapsed/Refractory Multiple Myeloma
Status: Enrolling
Updated:  4/5/2017
Medical College of Wisconsin - Clinical Cancer Center
mi
from
Milwaukee, WI
Study of ACY-1215 Alone and in Combination With Bortezomib and Dexamethasone in Multiple Myeloma
A Phase 1/2, Open-Label, Multicenter Study of ACY-1215 Administered Orally as Monotherapy and in Combination With Bortezomib and Dexamethasone for the Treatment of Relapsed or Relapsed/Refractory Multiple Myeloma
Status: Enrolling
Updated: 4/5/2017
Medical College of Wisconsin - Clinical Cancer Center
mi
from
Milwaukee, WI
Click here to add this to my saved trials